Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study

被引：0
|
作者：
Daisuke Sakai
Takeshi Omori
Soichi Fumita
Junya Fujita
Ryohei Kawabata
Jin Matsuyama
Hisateru Yasui
Motohiro Hirao
Tomono Kawase
Kentaro Kishi
Yoshiki Taniguchi
Yasuhiro Miyazaki
Junji Kawada
Hironaga Satake
Tomoko Miura
Akimitsu Miyake
Yukinori Kurokawa
Makoto Yamasaki
Tomomi Yamada
Taroh Satoh
Hidetoshi Eguchi
Yuichiro Doki
机构：
[1] Osaka University Graduate School of Medicine,
[2] Osaka International Cancer Institute,undefined
[3] Kindai University,undefined
[4] Sakai City Medical Center,undefined
[5] Osaka Rosai Hospital,undefined
[6] Higashiosaka City Medical Center,undefined
[7] Kobe City Medical Center General Hospital,undefined
[8] National Hospital Organization Osaka National Hospital,undefined
[9] Toyonaka Municipal Hospital,undefined
[10] Osaka Police Hospital,undefined
[11] Saiseikai Senri Hospital,undefined
[12] Osaka General Medical Center,undefined
[13] Yao Municipal Hospital,undefined
[14] Kansai Medical University,undefined
[15] Daiichi Sankyo Co.,undefined
[16] Ltd.,undefined
[17] Osaka University Hospital,undefined
[18] Yao Municipal Hospital,undefined
[19] Sakai City Medical Center,undefined
[20] Tohoku University School of Medicine,undefined
[21] Kansai Medical University,undefined
来源：
International Journal of Clinical Oncology | 2022年 / 27卷
关键词：
Gastric cancer; HER2 + ; Third- or later-line treatment; Nivolumab; Japan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1154 / 1163
页数：9
相关论文
共 50 条
  • [1] Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study
    Sakai, Daisuke
    Omori, Takeshi
    Fumita, Soichi
    Fujita, Junya
    Kawabata, Ryohei
    Matsuyama, Jin
    Yasui, Hisateru
    Hirao, Motohiro
    Kawase, Tomono
    Kishi, Kentaro
    Taniguchi, Yoshiki
    Miyazaki, Yasuhiro
    Kawada, Junji
    Satake, Hironaga
    Miura, Tomoko
    Miyake, Akimitsu
    Kurokawa, Yukinori
    Yamasaki, Makoto
    Yamada, Tomomi
    Satoh, Taroh
    Eguchi, Hidetoshi
    Doki, Yuichiro
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (07) : 1154 - 1163
  • [2] Effectiveness of third- or later-line therapy in patients with HER2-positive advanced gastric cancer: Results from an observational retrospective study in Japan
    Omori, Takeshi
    Sakai, Daisuke
    Fumita, Soichi
    Fujita, Junya
    Kawabata, Ryohei
    Matsuyama, Jin
    Yasui, Hisateru
    Hirao, Motohiro
    Kawase, Tomono
    Kishi, Kentaro
    Taniguchi, Hirokazu
    Miyazaki, Yasuhiro
    Miura, Tomoko
    Miyake, Akimitsu
    Kurokawa, Yukinori
    Yamasaki, Makoto
    Yamada, Tomomi
    Satoh, Taroh
    Eguchi, Hidetoshi
    Doki, Yuichiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [3] Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study
    Shimozaki, Keitaro
    Nakayama, Izuma
    Takahari, Daisuke
    Nagashima, Kengo
    Yoshino, Koichiro
    Fukuda, Koshiro
    Fukuoka, Shota
    Osumi, Hiroki
    Ogura, Mariko
    Wakatsuki, Takeru
    Ooki, Akira
    Shinozaki, Eiji
    Chin, Keisho
    Yamaguchi, Kensei
    [J]. JOURNAL OF GASTRIC CANCER, 2023, 23 (04) : 609 - 621
  • [4] Efficacy and safety of trastuzumab deruxtecan and nivolumab as third- or later-line treatment for HER2-positive advanced gastric cancer: A single-institution retrospective study.
    Shimozaki, Keitaro
    Nakayama, Izuma
    Takahari, Daisuke
    Nagashima, Kengo
    Yoshino, Koichiro
    Fukuda, Koshiro
    Fukuoka, Shota
    Osumi, Hiroki
    Ogura, Mariko
    Wakatsuki, Takeru
    Ooki, Akira
    Shinozaki, Eiji
    Chin, Keisho
    Yamaguchi, Kensei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 265 - 265
  • [5] Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)
    Nakayama, Takahiro
    Yoshinami, Tetsuhiro
    Yasojima, Hiroyuki
    Kittaka, Nobuyoshi
    Takahashi, Masato
    Ohtani, Shoichiro
    Kim, Seung Jin
    Kurakami, Hiroyuki
    Yamamoto, Naoko
    Yamada, Tomomi
    Takata, Takehiko
    Masuda, Norikazu
    [J]. BMC CANCER, 2021, 21 (01)
  • [6] Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)
    Takahiro Nakayama
    Tetsuhiro Yoshinami
    Hiroyuki Yasojima
    Nobuyoshi Kittaka
    Masato Takahashi
    Shoichiro Ohtani
    Seung Jin Kim
    Hiroyuki Kurakami
    Naoko Yamamoto
    Tomomi Yamada
    Takehiko Takata
    Norikazu Masuda
    [J]. BMC Cancer, 21
  • [7] Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada
    Gambaro, Karen
    Groleau, Melanie
    Mcnamara, Suzan
    Awan, Arif
    Salem, Maged
    Abdelsalam, Mahmoud
    St-Hilaire, Eve
    Vincent, Francois
    Carrier, Julie
    Mackay, Helen
    Provencher, Louise
    Boudreau, Dominique
    Hamilou, Zineb
    Saad, Fred
    Ferrario, Cristiano
    Batist, Gerald
    Marques, Maud
    [J]. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2023, 26 : 12078
  • [8] The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
    Ouyang, D. J.
    Chen, Q. T.
    Anwar, M.
    Xie, N.
    Ouyang, Q. C.
    Fan, P. Z.
    Qian, L. Y.
    Chen, G. N.
    Zhou, E. X.
    Guo, L.
    Gu, X. W.
    Ding, B. N.
    Yang, X. H.
    Liu, L. P.
    Deng, C.
    Xiao, Z.
    Li, J.
    Wang, Y. Q.
    Zeng, S.
    Wang, Shouman
    Yi, Wenjun
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [9] Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study
    Li, Chao
    Bian, Xiaoli
    Liu, Zhaoyun
    Wang, Xinzhao
    Song, Xiang
    Zhao, Wei
    Liu, Yansong
    Yu, Zhiyong
    [J]. CANCER MEDICINE, 2021, 10 (23): : 8352 - 8364
  • [10] Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis
    Rizzo, Alessandro
    Mollica, Veronica
    Ricci, Angela Dalia
    Maggio, Ilaria
    Massucci, Maria
    Limpe, Fabiola Lorena Rojas
    Di Fabio, Francesca
    Ardizzoni, Andrea
    [J]. FUTURE ONCOLOGY, 2020, 16 (02) : 4409 - 4418
12345